Kobayashi T, Gruessner A C, Wakai T, Sutherland D E R
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
College of Public Health, University of Arizona, Tucson, Arizona, USA.
Transplant Proc. 2014 Apr;46(3):948-53. doi: 10.1016/j.transproceed.2013.11.058.
The purposes of this study were to study and compare clinical and functional outcomes after simultaneous deceased donor pancreas and kidney transplantation (SPK DD), simultaneous deceased donor pancreas and living donor kidney transplantation (SPK DL), and simultaneous living donor pancreas and kidney transplantation (SPK LL).
From January 1, 1996 to September 1, 2005, 8918 primary, simultaneous pancreas and kidney transplantation (SPK) procedures were reported to the International Pancreas Transplant Registry. Of these, 8764 (98.3%) were SPK DD, 115 (1.3%) were SPK DL, and 39 (0.4%) were SPK LL. We compared these 3 groups with regard to several endpoints including patient and pancreas and kidney graft survival rates.
The 1-year and 3-year patient survival rates for SPK DD were 95% and 90%, 97% and 95% for SPK DL, and 100% and 100% for SPK LL recipients, respectively (P ≥ .07). The 1-year and 3-year pancreas graft survival rates for SPK DD were 84% and 77%, 83% and 71% for SPK DL, and 90% and 84% for SPK LL recipients, respectively (P ≥ .16). The 1-year and 3-year kidney graft survival rates for SPK DD were 92% and 84%, 94% and 86% for SPK DL, and 100% and 89% for SPK LL recipients, respectively (P ≥ .37).
Patient survival rates and graft survival rates for pancreas and kidney were similar among the 3 groups evaluated in this study.
本研究旨在研究并比较尸体供者同期胰肾联合移植（SPK DD）、尸体供者同期胰与活体供者肾联合移植（SPK DL）以及活体供者同期胰肾联合移植（SPK LL）后的临床及功能结局。
1996年1月1日至2005年9月1日期间，国际胰腺移植登记处共收到8918例初次同期胰肾联合移植（SPK）手术报告。其中，8764例（98.3%）为SPK DD，115例（1.3%）为SPK DL，39例（0.4%）为SPK LL。我们比较了这3组在多个终点指标方面的情况，包括患者以及胰腺和肾移植物的存活率。
SPK DD受者的1年和3年患者存活率分别为95%和90%，SPK DL受者分别为97%和95%，SPK LL受者分别为100%和100%（P≥0.07）。SPK DD受者的1年和3年胰腺移植物存活率分别为84%和77%，SPK DL受者分别为83%和71%，SPK LL受者分别为90%和84%（P≥0.16）。SPK DD受者的1年和3年肾移植物存活率分别为92%和84%，SPK DL受者分别为94%和86%，SPK LL受者分别为100%和89%（P≥0.37）。
本研究评估的3组患者的存活率以及胰腺和肾的移植物存活率相似。
